abstract |
The present invention relates to anthracene-9,10-dione dioxime compounds: 2-((3R, 5S)-for the treatment of cancer including myeloproliferative neoplasia, chronic myelogenous leukemia, and acute myeloid leukemia. The use of 3,5-dimethylpiperidin-1-ylsulfonyl) -7-((3S, 5R) -3,5-dimethylpiperidin-1-ylsulfonyl) anthracene-9,10-dionedioxime is disclosed. Such anthracene-9,10-dione dioxime compounds interfere with the interaction between transducin β-like protein 1 (TBL1) and the coactivator molecule β-catenin and treat β-catenin pathway related disorders For diagnosis, and prevention, it disrupts the Wnt / β-catenin pathway and inhibits the deregulated activity of this pathway. |